NewLink Genetics Corporation (NLNK) Rating Increased to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a neutral rating to an outperform rating in a report released on Friday, September 8th, Marketbeat reports. The brokerage currently has $22.00 price objective on the biotechnology company’s stock, up from their previous price objective of $8.00.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a hold rating to a buy rating and set a $12.00 target price on the stock in a report on Wednesday, June 7th. Cantor Fitzgerald set a $32.00 target price on shares of NewLink Genetics Corporation and gave the company a buy rating in a report on Sunday, June 4th. Jefferies Group LLC upgraded shares of NewLink Genetics Corporation from a hold rating to a buy rating and boosted their price objective for the stock from $7.00 to $26.00 in a report on Friday, September 8th. Finally, ValuEngine upgraded shares of NewLink Genetics Corporation from a sell rating to a hold rating in a report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $24.17.

NewLink Genetics Corporation (NASDAQ:NLNK) traded down 3.94% during mid-day trading on Friday, hitting $12.67. The stock had a trading volume of 4,209,589 shares. The company’s market cap is $372.76 million. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The company has a 50 day moving average price of $8.51 and a 200-day moving average price of $12.83.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. Equities analysts expect that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Rating Increased to Outperform at Robert W. Baird” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.truebluetribune.com/2017/09/17/newlink-genetics-corporation-nlnk-stock-rating-upgraded-by-robert-w-baird.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of NewLink Genetics Corporation by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after purchasing an additional 51,013 shares during the last quarter. Columbus Circle Investors increased its position in shares of NewLink Genetics Corporation by 72.5% in the 2nd quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after purchasing an additional 248,724 shares during the last quarter. State Street Corp increased its position in shares of NewLink Genetics Corporation by 1.2% in the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 4,630 shares during the last quarter. Northern Trust Corp increased its position in shares of NewLink Genetics Corporation by 4.0% in the 2nd quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after purchasing an additional 11,532 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in shares of NewLink Genetics Corporation in the 1st quarter worth about $5,127,000. 54.78% of the stock is owned by institutional investors.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply